These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 24476390)

  • 41. The prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone.
    Harari S; Caminati A; Confalonieri M; Poletti V; Vancheri C; Pesci A; Rogliani P; Luppi F; Agostini C; Rottoli P; Sanduzzi Zamparelli A; Sebastiani A; Della Porta R; Salton F; Messore B; Tomassetti S; Rosso R; Biffi A; Puxeddu E; Cerri S; Cinetto F; Refini RM; Bocchino M; Di Michele L; Specchia C; Albera C;
    Clin Respir J; 2019 Mar; 13(3):166-173. PubMed ID: 30675755
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and adverse events of pirfenidone in treating idiopathic pulmonary fibrosis.
    Ren H; Wang K; Yang H; Gao L
    Saudi Med J; 2017 Sep; 38(9):889-894. PubMed ID: 28889145
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2).
    Maher TM; Kreuter M; Lederer DJ; Brown KK; Wuyts W; Verbruggen N; Stutvoet S; Fieuw A; Ford P; Abi-Saab W; Wijsenbeek M
    BMJ Open Respir Res; 2019; 6(1):e000422. PubMed ID: 31179008
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.
    King TE; Safrin S; Starko KM; Brown KK; Noble PW; Raghu G; Schwartz DA
    Chest; 2005 Jan; 127(1):171-7. PubMed ID: 15653980
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases.
    Oltmanns U; Kahn N; Palmowski K; Träger A; Wenz H; Heussel CP; Schnabel PA; Puderbach M; Wiebel M; Ehlers-Tenenbaum S; Warth A; Herth FJ; Kreuter M
    Respiration; 2014; 88(3):199-207. PubMed ID: 25115833
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Predictors of Mortality Poorly Predict Common Measures of Disease Progression in Idiopathic Pulmonary Fibrosis.
    Ley B; Bradford WZ; Vittinghoff E; Weycker D; du Bois RM; Collard HR
    Am J Respir Crit Care Med; 2016 Sep; 194(6):711-8. PubMed ID: 26938706
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Idiopathic pulmonary fibrosis and pirfenidone.
    Collard HR
    Eur Respir J; 2010 Apr; 35(4):728-9. PubMed ID: 20356985
    [No Abstract]   [Full Text] [Related]  

  • 48. Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.
    Durheim MT; Collard HR; Roberts RS; Brown KK; Flaherty KR; King TE; Palmer SM; Raghu G; Snyder LD; Anstrom KJ; Martinez FJ;
    Lancet Respir Med; 2015 May; 3(5):388-96. PubMed ID: 25890798
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of Perioperative Pirfenidone Treatment in Lung Cancer Patients With Idiopathic Pulmonary Fibrosis.
    Iwata T; Yoshida S; Fujiwara T; Wada H; Nakajima T; Suzuki H; Yoshino I
    Ann Thorac Surg; 2016 Dec; 102(6):1905-1910. PubMed ID: 27546601
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Endogenous blood maximal interferon-gamma production may predict response to interferon-gamma 1beta treatment in patients with idiopathic pulmonary fibrosis.
    Luppi F; Losi M; D'Amico R; Fabbri LM; Richeldi L
    Sarcoidosis Vasc Diffuse Lung Dis; 2009 Jul; 26(1):64-8. PubMed ID: 19960790
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis.
    Dempsey TM; Sangaralingham LR; Yao X; Sanghavi D; Shah ND; Limper AH
    Am J Respir Crit Care Med; 2019 Jul; 200(2):168-174. PubMed ID: 31150266
    [No Abstract]   [Full Text] [Related]  

  • 52. [Expectation of new treatments for idiopathic interstitial pneumonias].
    Azuma A
    Nihon Ronen Igakkai Zasshi; 2005 Jan; 42(1):27-30. PubMed ID: 15732351
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pirfenidone improves survival in IPF: results from a real-life study.
    Margaritopoulos GA; Trachalaki A; Wells AU; Vasarmidi E; Bibaki E; Papastratigakis G; Detorakis S; Tzanakis N; Antoniou KM
    BMC Pulm Med; 2018 Nov; 18(1):177. PubMed ID: 30470213
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Is pirfenidone effective for idiopathic pulmonary fibrosis?
    Jeldres A; Labarca G
    Medwave; 2017 Jan; 17(Suppl1):e6843. PubMed ID: 28112713
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pirfenidone: significant treatment effects in idiopathic pulmonary fibrosis.
    Hilberg O; Simonsen U; du Bois R; Bendstrup E
    Clin Respir J; 2012 Jul; 6(3):131-43. PubMed ID: 22697264
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The big clinical trials in idiopathic pulmonary fibrosis.
    Luppi F; Spagnolo P; Cerri S; Richeldi L
    Curr Opin Pulm Med; 2012 Sep; 18(5):428-32. PubMed ID: 22759771
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pirfenidone: Clinical trials and clinical practice in patients with idiopathic pulmonary fibrosis.
    Bando M
    Respir Investig; 2016 Sep; 54(5):298-304. PubMed ID: 27566376
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Study design implications of death and hospitalization as end points in idiopathic pulmonary fibrosis.
    Collard HR; Brown KK; Martinez FJ; Raghu G; Roberts RS; Anstrom KJ
    Chest; 2014 Nov; 146(5):1256-1262. PubMed ID: 25144827
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis.
    Spagnolo P; Kreuter M; Maher TM; Wuyts W; Bonella F; Corte TJ; Kopf S; Weycker D; Kirchgaessler KU; Ryerson CJ
    Respiration; 2018; 96(4):314-322. PubMed ID: 30025392
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials.
    Richeldi L; Cottin V; du Bois RM; Selman M; Kimura T; Bailes Z; Schlenker-Herceg R; Stowasser S; Brown KK
    Respir Med; 2016 Apr; 113():74-9. PubMed ID: 26915984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.